Recent reports revealed that the infection rates between adults and children were similar since the novel coronavirus hit the world in 2019, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.

Cambridge, Massachusetts-based Thrive Earlier Detection released data from the DETECT-A study evaluating the company’s blood test to screen for multiple types of cancers. The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.

HCB Health President Nancy Beesley recently shared insights with Med Ad News about how her agency promotes diversity and what the industry needs to improve on.

  Diversity of Women Veterans’ Experiences Myths vs Reality   In this paper, we tackle one of the most common myths about VA healthcare.   At Ipsos Public Affairs, we partner with the Department of Veterans Affairs (VA) to understand how Veterans utilize and experience VA healthcare services. Women are projected to be the fastest-growing […]

Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community.

Novoheart and AstraZeneca agreed on a collaboration to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women.

Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).

GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.

Join the HBA for a unique discussion regarding “balance,” the overarching theme for International Women’s Day 2019.

Evofem Biosciences shares rose 38 percent after the company’s birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.